Literature DB >> 9652752

Induction of apoptosis by taxol and cisplatin and effect on cell cycle-related proteins in cisplatin-sensitive and -resistant human ovarian cells.

N Zaffaroni1, R Silvestrini, L Orlandi, A Bearzatto, D Gornati, R Villa.   

Abstract

The effect of taxol (TX) and cisplatin (CDDP), singly or in association, was assessed on two human ovarian cancer cell lines, one sensitive (A2780) and one resistant (A2780 cp8) to CDDP. Cell lines showed a similar sensitivity to TX, whereas different cytotoxicity results were obtained in the two cell lines as a function of TX and CDDP sequence. Specifically, TX followed by CDDP induced simply additive effects in both cell lines, whereas the opposite sequence produced antagonistic effects in A2780 cells and synergistic effects in A2780 cp8 cells. TX, with or without CDDP, induced oligonucleosomal DNA fragmentation typical of the apoptotic process, but the biochemical mechanisms undergoing apoptosis were different in the two cell lines. In fact, in A2780 cells, TX (with or without CDDP) treatment markedly increased p53 as well as p21waf1 protein expression. In A2780 cp8 cells, drug treatment enhanced p53 levels, whereas the expression of p21waf1 was always undetectable at mRNA and protein levels. In the latter cell line, a premature activation of p34cdc2 kinase was observed in correspondence with the drug-induced increase in the S-phase cell fraction. Such an activation was not ascribable to an increase in the overall expression of p34cdc2 or cyclin B1 proteins, but to a dephosphorylation of p34cdc2 kinase. Overall, our results indicate that TX-induced apoptosis in human ovarian cancer cells may be sustained by different events at the cell cycle-control level.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9652752      PMCID: PMC2150188          DOI: 10.1038/bjc.1998.230

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  34 in total

Review 1.  Universal control mechanism regulating onset of M-phase.

Authors:  P Nurse
Journal:  Nature       Date:  1990-04-05       Impact factor: 49.962

Review 2.  Driving the cell cycle: M phase kinase, its partners, and substrates.

Authors:  B Lewin
Journal:  Cell       Date:  1990-06-01       Impact factor: 41.582

3.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.

Authors:  T C Chou; P Talalay
Journal:  Adv Enzyme Regul       Date:  1984

4.  Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues.

Authors:  B C Behrens; T C Hamilton; H Masuda; K R Grotzinger; J Whang-Peng; K G Louie; T Knutsen; W M McKoy; R C Young; R F Ozols
Journal:  Cancer Res       Date:  1987-01-15       Impact factor: 12.701

5.  Comparative in vitro cytotoxicity of taxol and Taxotere against cisplatin-sensitive and -resistant human ovarian carcinoma cell lines.

Authors:  L R Kelland; G Abel
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

6.  Participation of p53 protein in the cellular response to DNA damage.

Authors:  M B Kastan; O Onyekwere; D Sidransky; B Vogelstein; R W Craig
Journal:  Cancer Res       Date:  1991-12-01       Impact factor: 12.701

7.  Taxol: a novel radiation sensitizer.

Authors:  R B Tishler; P B Schiff; C R Geard; E J Hall
Journal:  Int J Radiat Oncol Biol Phys       Date:  1992       Impact factor: 7.038

8.  The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA.

Authors:  S Waga; G J Hannon; D Beach; B Stillman
Journal:  Nature       Date:  1994-06-16       Impact factor: 49.962

9.  A phase II trial of taxol in metastatic melanoma.

Authors:  S S Legha; S Ring; N Papadopoulos; M Raber; R S Benjamin
Journal:  Cancer       Date:  1990-06-01       Impact factor: 6.860

10.  Mechanism of cis-diamminedichloroplatinum(II)-induced cytotoxicity: role of G2 arrest and DNA double-strand breaks.

Authors:  C M Sorenson; A Eastman
Journal:  Cancer Res       Date:  1988-08-15       Impact factor: 12.701

View more
  7 in total

1.  Synthesis of stress proteins in hyperthermia in the presence of cytotoxic agents.

Authors:  D A Mavletova; G A Dvorkin
Journal:  Dokl Biochem Biophys       Date:  2001 Jul-Aug       Impact factor: 0.788

2.  Focal adhesion kinase silencing augments docetaxel-mediated apoptosis in ovarian cancer cells.

Authors:  Jyotsnabaran Halder; Charles N Landen; Susan K Lutgendorf; Yang Li; Nicholas B Jennings; Dominic Fan; Gina M Nelkin; Rosemarie Schmandt; Michael D Schaller; Anil K Sood
Journal:  Clin Cancer Res       Date:  2005-12-15       Impact factor: 12.531

3.  Addition of 5-fluorouracil to doxorubicin-paclitaxel sequence increases caspase-dependent apoptosis in breast cancer cell lines.

Authors:  Wainer Zoli; Paola Ulivi; Anna Tesei; Francesco Fabbri; Marco Rosetti; Roberta Maltoni; Donata Casadei Giunchi; Luca Ricotti; Giovanni Brigliadori; Ivan Vannini; Dino Amadori
Journal:  Breast Cancer Res       Date:  2005-06-22       Impact factor: 6.466

4.  Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin.

Authors:  C F O'Neill; B Koberle; J R Masters; L R Kelland
Journal:  Br J Cancer       Date:  1999-12       Impact factor: 7.640

5.  3-Hydroxyterphenyllin, a natural fungal metabolite, induces apoptosis and S phase arrest in human ovarian carcinoma cells.

Authors:  Yaomin Wang; Casey Compton; Gary O Rankin; Stephen J Cutler; Yon Rojanasakul; Youying Tu; Yi Charlie Chen
Journal:  Int J Oncol       Date:  2017-03-02       Impact factor: 5.650

6.  Anti-proliferative activity and cell cycle arrest induced by evodiamine on paclitaxel-sensitive and -resistant human ovarian cancer cells.

Authors:  Zhang-Feng Zhong; Wen Tan; Sheng-Peng Wang; Wen-An Qiang; Yi-Tao Wang
Journal:  Sci Rep       Date:  2015-11-10       Impact factor: 4.379

7.  Temperature-sensitive ovarian carcinoma cell line (OvBH-1).

Authors:  Julia K Bar; Antonina Harlozinska; Sabine Kartarius; Mathias Montenarh; Ewa Wyrodek; Jan M Rodriguez Parkitna; Marian Kochman; Andrzej Ozyhar
Journal:  Jpn J Cancer Res       Date:  2002-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.